Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-05-21 Board/Management Inform…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director Declaration
Board/Management Information Classification · 1% confidence The document is a short regulatory announcement (RNS) from AstraZeneca PLC regarding a change in the board/management composition, specifically the appointment of the CEO to an external board. This falls under the category of Board/Management Information (MANG).
2025-05-21 English
ACQUISITION OF ESOBIOTEC COMPLETED
Foreign Filer Report
2025-05-20 English
Acquisition of EsoBiotec completed
M&A Activity Classification · 1% confidence The document is an official announcement from AstraZeneca regarding the completion of an acquisition of a biotechnology company (EsoBiotec). It details the financial terms of the transaction, the strategic rationale, and the impact on the company's operations. Since this document describes a merger and acquisition activity, it falls under the M&A Activity category.
2025-05-20 English
IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER
Foreign Filer Report
2025-05-09 English
Imfinzi improved DFS in early bladder cancer
Regulatory Filings Classification · 1% confidence The document is an official announcement from AstraZeneca regarding the results of a Phase III clinical trial (POTOMAC). It is distributed via the London Stock Exchange's Regulatory News Service (RNS), as indicated by the 'RNS Number' header and the footer text. While it contains clinical trial data, it is a press release-style announcement of results rather than a full scientific audit report or a quarterly financial report. Under the provided classification rules, specifically the 'Regulatory Filings' category, this document fits as a general regulatory announcement.
2025-05-09 English
ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER
Foreign Filer Report
2025-05-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.